REPLIGEN CORP
Close on Oct 19, 2026
- Market cap
- $9.99B
- P/E (TTM)
- 205.2
- Dividend yield
- –
About Repligen
Biological Products, (No Diagnostic Substances), SIC 2836
Repligen Corporation is a life sciences company that develops and supplies bioprocessing technologies and systems used in biological drug manufacturing. Its product offerings include filtration products, chromatography solutions, process analytics products, and proteins. These offerings serve customers across the biopharmaceutical and biotechnology industries, specifically supporting operations within the bioprocessing market.
The company is based in the United States, maintaining its corporate headquarters in Waltham, Massachusetts. Repligen conducts international business across multiple geographical markets, with reported commercial operations and regional exposure spanning North America, Europe, and the Asia-Pacific and rest-of-world regions, including entity activity in the Netherlands and Sweden.
Summary of the business section of Repligen's latest annual report, written by StockData.
Company profile
Company
- Legal name
- REPLIGEN CORP
- Founded
- 1981
- Headquarters
- Waltham, MA
- Address
- 41 Seyon Street, Building 1, Suite 100 02453
- Phone
- (781) 449-9560
- Website
- www.repligen.com
- Employees
- 2,000, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts, United States
Stock & identifiers
- Ticker
- RGEN
- Exchange
- Nasdaq
- IPO date
- Apr 29, 1986
- Shares outstanding
- 56M, Jul 24, 2026
- Public float
- $6.00B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 730272
- CUSIP
- 759916109
- ISIN
- US7599161095
- LEI
- 54930006QJ0T5AUO1E71
- EIN
- 04-2729386
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Olivier Loeillot | Chief Executive Officer, Director | 48,369 |
| Jason K. Garland | CFO | 18,408 |
| Violetta Hughes | CHIEF ACCOUNTING OFFICER | 6,331 |
| Brian Robb Douglass | CHIEF PRODUCT OFFICER | 7,985 |
| Ralf Kuriyel | Senior VP, R&D | 20,062 |
| James Bylund | Chief Operating Officer | 25,423 |
| Nicolas Barthelemy | Director | 5,436 |
| Manner Carrie Eglinton | Director | 5,461 |
| Rohin Mhatre | Director | 5,014 |
| Martin D. Madaus | Director | 8,392 |
| Karen A. Dawes | Director | 92,816 |
| Glenn P. Muir | Director | 40,051 |
| Konstantin Konstantinov | Director | 3,889 |
| Margaret Pax | Director | 3,011 |
| Anthony Hunt | Director | 89,062 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr. Loeillot | $6.11M | $8.69M | $2.50M | $86 | $125 |
| FY2025 Olivier Loeillot | $6.11M | $8.69M | $2.50M | $86 | $125 |
| FY2024 Olivier Loeillot | $7.18M | $5.13M | $2.24M | $156 | $114 |
| FY2024 Tony JHunt | $20.30M | $921.14K | $2.24M | $156 | $114 |
| FY2023 Mr. Loeillot | $7.93M | $8.20M | $2.78M | $194 | $115 |
| FY2023 Tony JHunt | $7.93M | $8.20M | $2.78M | $194 | $115 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“We have approximately 2,000 employees and operate globally with offices and manufacturing sites located at multiple locations in the United States, Europe and Asia.”
Corporate history
Events identified from SEC filings